Extended-field radiation therapy for carcinoma of the cervix

E. Podczaski, J. A. Stryker, P. Kaminski, B. Ndubisi, J. Larson, Koenraad De Geest, J. Sorosky, R. Mortel

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The survival of cervical carcinoma patients with paraaortic/high common iliac nodal metastases was evaluated by retrospective chart review during a 13-year interval. Thirty-three patients with cervical carcinoma and surgically documented nodal metastases received primary, extended-field radiation therapy. Overall 2-year and 5-year actuarial survival rates after diagnosis were 37% and 31%, respectively. Survival was analyzed in terms of the variables patient age, clinical stage, tumor histologic type, the presence of enlarged paraaortic/high common iliac lymph nodes, the extent of nodal involvement (microscopic versus macroscopic), the presence of intraperitoneal disease, and whether intracavitary brachytherapy was administered. The use of intracavitary radiation therapy was associated with improved local control and survival (P = 0.017). None of the other variables were statistically related to patient survival. Twenty-two of the patients died of cervical cancer and five are surviving without evidence of cancer. Four patients died of intercurrent disease. Two patients developed bowel-related radiation complications; both patients received chemotherapy concurrent with the radiation therapy. One of the two patients died of radiation enteritis. The use of extended-field radiation therapy does benefit a small group of patients and may result in extented patient survival.

Original languageEnglish (US)
Pages (from-to)251-258
Number of pages8
JournalCancer
Volume66
Issue number2
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Cervix Uteri
Radiotherapy
Carcinoma
Survival
Radiation
Neoplasm Metastasis
Enteritis
Brachytherapy
Uterine Cervical Neoplasms
Neoplasms
Survival Rate
Lymph Nodes
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Podczaski, E., Stryker, J. A., Kaminski, P., Ndubisi, B., Larson, J., De Geest, K., ... Mortel, R. (1990). Extended-field radiation therapy for carcinoma of the cervix. Cancer, 66(2), 251-258. https://doi.org/10.1002/1097-0142(19900715)66:2<251::AID-CNCR2820660210>3.0.CO;2-E

Extended-field radiation therapy for carcinoma of the cervix. / Podczaski, E.; Stryker, J. A.; Kaminski, P.; Ndubisi, B.; Larson, J.; De Geest, Koenraad; Sorosky, J.; Mortel, R.

In: Cancer, Vol. 66, No. 2, 1990, p. 251-258.

Research output: Contribution to journalArticle

Podczaski, E, Stryker, JA, Kaminski, P, Ndubisi, B, Larson, J, De Geest, K, Sorosky, J & Mortel, R 1990, 'Extended-field radiation therapy for carcinoma of the cervix', Cancer, vol. 66, no. 2, pp. 251-258. https://doi.org/10.1002/1097-0142(19900715)66:2<251::AID-CNCR2820660210>3.0.CO;2-E
Podczaski, E. ; Stryker, J. A. ; Kaminski, P. ; Ndubisi, B. ; Larson, J. ; De Geest, Koenraad ; Sorosky, J. ; Mortel, R. / Extended-field radiation therapy for carcinoma of the cervix. In: Cancer. 1990 ; Vol. 66, No. 2. pp. 251-258.
@article{b04828df32cd4bd28ed737e8cc3b3d98,
title = "Extended-field radiation therapy for carcinoma of the cervix",
abstract = "The survival of cervical carcinoma patients with paraaortic/high common iliac nodal metastases was evaluated by retrospective chart review during a 13-year interval. Thirty-three patients with cervical carcinoma and surgically documented nodal metastases received primary, extended-field radiation therapy. Overall 2-year and 5-year actuarial survival rates after diagnosis were 37{\%} and 31{\%}, respectively. Survival was analyzed in terms of the variables patient age, clinical stage, tumor histologic type, the presence of enlarged paraaortic/high common iliac lymph nodes, the extent of nodal involvement (microscopic versus macroscopic), the presence of intraperitoneal disease, and whether intracavitary brachytherapy was administered. The use of intracavitary radiation therapy was associated with improved local control and survival (P = 0.017). None of the other variables were statistically related to patient survival. Twenty-two of the patients died of cervical cancer and five are surviving without evidence of cancer. Four patients died of intercurrent disease. Two patients developed bowel-related radiation complications; both patients received chemotherapy concurrent with the radiation therapy. One of the two patients died of radiation enteritis. The use of extended-field radiation therapy does benefit a small group of patients and may result in extented patient survival.",
author = "E. Podczaski and Stryker, {J. A.} and P. Kaminski and B. Ndubisi and J. Larson and {De Geest}, Koenraad and J. Sorosky and R. Mortel",
year = "1990",
doi = "10.1002/1097-0142(19900715)66:2<251::AID-CNCR2820660210>3.0.CO;2-E",
language = "English (US)",
volume = "66",
pages = "251--258",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Extended-field radiation therapy for carcinoma of the cervix

AU - Podczaski, E.

AU - Stryker, J. A.

AU - Kaminski, P.

AU - Ndubisi, B.

AU - Larson, J.

AU - De Geest, Koenraad

AU - Sorosky, J.

AU - Mortel, R.

PY - 1990

Y1 - 1990

N2 - The survival of cervical carcinoma patients with paraaortic/high common iliac nodal metastases was evaluated by retrospective chart review during a 13-year interval. Thirty-three patients with cervical carcinoma and surgically documented nodal metastases received primary, extended-field radiation therapy. Overall 2-year and 5-year actuarial survival rates after diagnosis were 37% and 31%, respectively. Survival was analyzed in terms of the variables patient age, clinical stage, tumor histologic type, the presence of enlarged paraaortic/high common iliac lymph nodes, the extent of nodal involvement (microscopic versus macroscopic), the presence of intraperitoneal disease, and whether intracavitary brachytherapy was administered. The use of intracavitary radiation therapy was associated with improved local control and survival (P = 0.017). None of the other variables were statistically related to patient survival. Twenty-two of the patients died of cervical cancer and five are surviving without evidence of cancer. Four patients died of intercurrent disease. Two patients developed bowel-related radiation complications; both patients received chemotherapy concurrent with the radiation therapy. One of the two patients died of radiation enteritis. The use of extended-field radiation therapy does benefit a small group of patients and may result in extented patient survival.

AB - The survival of cervical carcinoma patients with paraaortic/high common iliac nodal metastases was evaluated by retrospective chart review during a 13-year interval. Thirty-three patients with cervical carcinoma and surgically documented nodal metastases received primary, extended-field radiation therapy. Overall 2-year and 5-year actuarial survival rates after diagnosis were 37% and 31%, respectively. Survival was analyzed in terms of the variables patient age, clinical stage, tumor histologic type, the presence of enlarged paraaortic/high common iliac lymph nodes, the extent of nodal involvement (microscopic versus macroscopic), the presence of intraperitoneal disease, and whether intracavitary brachytherapy was administered. The use of intracavitary radiation therapy was associated with improved local control and survival (P = 0.017). None of the other variables were statistically related to patient survival. Twenty-two of the patients died of cervical cancer and five are surviving without evidence of cancer. Four patients died of intercurrent disease. Two patients developed bowel-related radiation complications; both patients received chemotherapy concurrent with the radiation therapy. One of the two patients died of radiation enteritis. The use of extended-field radiation therapy does benefit a small group of patients and may result in extented patient survival.

UR - http://www.scopus.com/inward/record.url?scp=0025280577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025280577&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19900715)66:2<251::AID-CNCR2820660210>3.0.CO;2-E

DO - 10.1002/1097-0142(19900715)66:2<251::AID-CNCR2820660210>3.0.CO;2-E

M3 - Article

C2 - 2369710

AN - SCOPUS:0025280577

VL - 66

SP - 251

EP - 258

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -